Skip to Content

Thermo Fisher Scientific Inc TMO

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Thermo Fisher Scientific Sees Strong Performance in Q4 as COVID-19 Windfall Continues

Alex Morozov, CFA Regional Director

Analyst Note

| Alex Morozov, CFA |

We are likely to slightly raise our fair value estimate for narrow-moat Thermo Fisher Scientific following the release of fourth-quarter and full-year results. The company delivered strong performance, supported by $3.2 billion in COVID-19 pandemic response revenue in the quarter alone.  We continue to see the shares as overvalued.

Read Full Analysis

Company Profile

Business Description

Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (15%); life science solutions (36%); and lab products and services (40%).

Contact
168 Third Avenue
Waltham, MA, 02451
T +1 781 622-1000
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings Dec 31, 2020
Fiscal Year End Dec 31, 2020
Stock Type Aggressive Growth
Employees 75,000

Related